Literature DB >> 21439763

A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies.

Guglielmo Consales1, Elena Gramigni2, Lucia Zamidei3, Daniela Bettocchi2, Angelo Raffaele De Gaudio3.   

Abstract

PURPOSE: Multidrug-resistant Acinetobacter baumannii (MRAB) is an emerging cause of intensive care unit (ICU) outbreaks. Patients are the main reservoirs, inducing cross transmission. We describe an MRAB outbreak that occurred in the Prato Hospital ICU in June to August 2009.
MATERIALS AND METHODS: The ICU consists of 2 separated 4-bed rooms (rooms A and B). The MRAB-positive patients were included in our study. During the outbreak, infection control measures were enhanced; patients and environmental screenings were performed. A 6-month follow-up was carried out.
RESULTS: Four of 26 patients admitted during the outbreak were MRAB positive. All patients were located in room A; no case was detected in room B either in the hospital or during the follow-up. Management included closure to new admissions, reinforcement of infection control measures, patient and environmental screenings, discharge of room B MRAB-negative patients for at least 5 days after the first case identification. All isolates were carbapenems resistant and tigecycline and colistin susceptible. All patients received tigecycline: 2 were successfully treated, 1 died because of preexisting illness, and 1 developed resistance and recovered after colistin therapy.
CONCLUSIONS: Enhanced infection control measures and adequate antibiotic strategy limited the outbreak. Tigecycline allowed rapid recovery. Nevertheless, resistance ensued; so colistin remained the only therapeutic option. However, pan-drug resistance has been reported.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21439763     DOI: 10.1016/j.jcrc.2010.12.016

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  15 in total

1.  Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.

Authors:  Yan Bai; Bin Liu; Tianlin Wang; Yun Cai; Beibei Liang; Rui Wang; Youning Liu; Jin Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

4.  Acinetobacter baumannii Genomic Sequence-Based Core Genome Multilocus Sequence Typing Using Ridom SeqSphere+ and Antimicrobial Susceptibility Prediction in ARESdb.

Authors:  Madiha Fida; Scott A Cunningham; Stephan Beisken; Andreas E Posch; Nicholas Chia; Patricio R Jeraldo; Matthew P Murphy; Nicole M Zinsmaster; Robin Patel
Journal:  J Clin Microbiol       Date:  2022-07-12       Impact factor: 11.677

5.  Emergence of concurrent infections with colistin-resistant ESBL-positive Klebsiella pneumoniae and OXA-23-producing Acinetobacter baumannii sensitive to colistin only in a Romanian cardiac intensive care unit.

Authors:  D Timofte; M Dan; I E Maciuca; L Ciucu; E R Dabija; E Guguianu; C V Panzaru
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-04       Impact factor: 3.267

6.  Molecular characterisation and control of Acinetobacter baumannii isolates resistant to multi-drugs emerging in inter-intensive care units.

Authors:  Ayşe Ertürk; Ayşegül Çopur Çiçek; Aziz Gümüş; Erkan Cüre; Ahmet Şen; Aysel Kurt; Alper Karagöz; Nebahat Aydoğan; Cemal Sandallı; Rıza Durmaz
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-07-22       Impact factor: 3.944

7.  Characterising the Transmission Dynamics of Acinetobacter baumannii in Intensive Care Units Using Hidden Markov Models.

Authors:  Tan N Doan; David C M Kong; Caroline Marshall; Carl M J Kirkpatrick; Emma S McBryde
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  A gloves-associated outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit in Guangdong, China.

Authors:  Dan Ye; Jinglan Shan; Yongbo Huang; Jianchun Li; Changan Li; Xiaoqing Liu; Weiqun He; Yimin Li; Pu Mao
Journal:  BMC Infect Dis       Date:  2015-04-11       Impact factor: 3.090

9.  Treatment of wounds colonized by multidrug resistant organisms in immune-compromised patients: a retrospective case series.

Authors:  Marco Pignatti; Giorgio Enrico Gerunda; Gianluca Rompianesi; Nicola De Ruvo; Fabrizio Di Benedetto; Mauro Codeluppi; Decenzio Bonucchi; Lucrezia Pacchioni; Pietro Loschi; Cristina Malaventura; Giorgio De Santis
Journal:  Patient Saf Surg       Date:  2013-09-03

10.  Draft Genome Sequence of Multidrug-Resistant Acinetobacter baumannii Strain MMC4, Isolated from a Patient in Tennessee.

Authors:  Sammed N Mandape; Dana R Marshall; L Leon Dent; Siddharth Pratap
Journal:  Genome Announc       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.